Vivanza Biosci.

Market Cap: Micro Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE984E01035
NSEID:
BSEID: 530057
View on BSE

INR

1.95

-0.03 (-1.52%)

BSENSE

Mar 13

BSE+NSE Vol: 6.42 k

Access older stock analysis version

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Brawn Biotech

Colinz Labs

Beryl Drugs

Unjha Formul.

Vivanza Biosci.

Adline Chem Lab

Parmax Pharma

Decipher Labs

Genomic Valley

Ganga Pharma.

Satiate Agri

Why is Vivanza Biosciences Ltd ?

Weak Long Term Fundamental Strength with a -4.85% CAGR growth in Operating Profits over the last 5 years

Low ability to service debt as the company has a high Debt to EBITDA ratio of 5.05 times
The company has been able to generate a Return on Equity (avg) of 9.70% signifying low profitability per unit of shareholders funds

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -9.30% returns in the last 1 year, the stock has also underperformed BSE500 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Vivanza Biosci. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Vivanza Biosci.

-9.3%

-0.19

48.24%

Sensex

1.0%

0.08

12.13%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

53.38%

EBIT Growth (5y)

-4.85%

EBIT to Interest (avg)

0.43

Debt to EBITDA (avg)

0.68

Net Debt to Equity (avg)

2.07

Sales to Capital Employed (avg)

2.22

Tax Ratio

7.14%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

0.00%

ROCE (avg)

3.62%

ROE (avg)

9.70%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.69

EV to EBIT

-17.34

EV to EBITDA

-17.34

EV to Capital Employed

1.23

EV to Sales

0.16

PEG Ratio

Dividend Yield

ROCE (Latest)

-0.64%

ROE (Latest)

-6.72%

Loading Valuation Snapshot...

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Moving Averages

Bearish (Daily)

KST

Bearish

Mildly Bullish

Dow Theory

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

14What is working for the Company

NET SALES(Latest six months)

Higher at Rs 100.61 cr

PAT(Latest six months)

Higher at Rs 0.76 cr

0What is not working for the Company

NO KEY NEGATIVE TRIGGERS

Loading Valuation Snapshot...

Here's what is working for Vivanza Biosci.

Net Sales - Latest six months

At Rs 100.61 cr has Grown at 2,135.78%

Year on Year (YoY)

MOJO Watch

Sales trend is very positive

Net Sales (Rs Cr)

Net Sales - Latest six months

Higher at Rs 100.61 cr

than preceding 12 month period ended Dec 2025 of Rs 13.92 cr

MOJO Watch

In the half year the company has already crossed sales of the previous twelve months

Net Sales (Rs Cr)

Profit After Tax (PAT) - Latest six months

Higher at Rs 0.76 cr

than preceding 12 month period ended Dec 2025 of Rs -0.85 cr

MOJO Watch

In the half year the company has already crossed PAT of the previous twelve months

PAT (Rs Cr)